Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine; No Financial Terms Disclosed
Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging
Wedbush Initiates Coverage On Omega Therapeutics with Outperform Rating, Announces Price Target of $36
Wedbush analyst Robert Driscoll initiates coverage on Omega Therapeutics (NASDAQ:OMGA) with a Outperform rating and announces Price Target of $36.
Jefferies Initiates Coverage On Omega Therapeutics with Buy Rating, Announces Price Target of $30
Jefferies analyst Chris Howerton initiates coverage on Omega Therapeutics (NASDAQ:OMGA) with a Buy rating and announces Price Target of $30.
Piper Sandler Initiates Coverage On Omega Therapeutics with Overweight Rating, Announces Price Target of $30
Piper Sandler analyst Edward Tenthoff initiates coverage on Omega Therapeutics (NASDAQ:OMGA) with a Overweight rating and announces Price Target of $30.
Goldman Sachs Initiates Coverage On Omega Therapeutics with Neutral Rating, Announces Price Target of $22
Goldman Sachs analyst Salveen Richter initiates coverage on Omega Therapeutics (NASDAQ:OMGA) with a Neutral rating and announces Price Target of $22.
The Week Ahead In Biotech: Cara FDA Decision, Ascendis Earnings, Aileron Data Presentation And More
Biotech stocks swayed back and forth before ending the week lower. With earnings news dying down and an empty initial public offerings calendar, it was broader market cues, clinical readouts and regulatory actions that moved stocks during the week.
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)